Auteur / david.smadja
-
Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients ?
Chiara Gardin 1,2, Letizia Ferroni 1,2, Juan Carlos Chachques 3 and Barbara Zavan 1,2,* Abstract : Coronavirus disease 2019 (COVID-19) is a pandemic viral disease originated in Wuhan, China, in December 2019,…
-
Autoregulation of Pulsatile Bioprosthetic Total Artificial Heart is Involved in Endothelial Homeostasis Preservation
David M. Smadja 1, Richard Chocron 2, Elisa Rossi 3 Bastien Poitier 4 Yuri Pya 5 Mahabbat Bekbossynova 5 Christophe Peronino 1 Jeanne Rancic 1 Jean Christian Roussel 6 Michel Kindo7 Nicolas…
-
Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart
Ivan Netuka, MD, PhD, Yuriy Pya, MD, Makhabbat Bekbossynova, MD, Peter Ivak, MD, PhD, Miroslav Konarik, MD, Finn Gustafsson, MD, PhD, David M. Smadja, PharmD, PhD, Piet Jansen, MD, PhD, and Christian…
-
Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study
J.‑L. Diehl 1,2*, N. Peron 3, R. Chocron 4,5, B. Debuc 6 , E. Guerot 3, C. Hauw‑Berlemont 3, B. Hermann 3 , J. L. Augy 3 , R. Younan 3 ,…
-
Severity of endothelial dysfunction is associated with the occurrence of hemorrhagic complications in COPD patients treated by extracorporeal CO2 removal
Jean‑Luc Diehl 1,2* , Jean Loup Augy 1 , Nadia Rivet 2,3, Coralie Guerin 2,4, Richard Chocron 5,6 and David M. Smadja 2,3 Abstract : In chronic obstructive pulmonary disease (COPD) patients…
-
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
In two articles reporting the results of GALILEO (Jan. 9 issue), Dangas et al.1 and De Backer et al.2 provide conflicting results on the benefit of rivaroxaban in transcatheter aortic-valve replacement (TAVR).…
-
Stem Cells Therapeutic Applications – Chapter 11 – David M.Smadja
Mariusz Z. Ratajczak Stem Cell Institute at James Graham Brown Cancer Center University of Louisville Louisville, KY, USA. It is obvious that stem cells and regenerative medicine have become the “hottest” contemporary…
-
Targeting endothelial thioredoxin‑interacting protein (TXNIP) protects from metabolic disorder‑related impairment of vascular function and post‑ischemic revascularisation
Alison Domingues · Catherine Boisson‑Vidal · Perrine Marquet de Rouge · Blandine Dizier · Jérémy Sadoine · Virginie Mignon · Emilie Vessières · Daniel Henrion · Virginie Escriou · Pascal Bigey · Catherine Chaussain · David M. Smadja · Valérie Nivet‑Antoine. Although thioredoxin-interacting protein (TXNIP) is involved in a variety of biological functions, the contribution of endothelial TXNIP has not…
-
Elastomeric cardiopatch scaffold for myocardial repair and ventricular support
OBJECTIVES: Prevention of postischaemic ventricular dilatation progressing towards pathological remodelling is necessary to decrease ventricular wall deterioration. Myocardial tissue engineering may play a therapeutic role due to its capacity to replace the…
-
Valproic Acid Decreases Endothelial Colony Forming Cells Differentiation and Induces Endothelial-to-Mesenchymal Transition-like Process
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor is a widely used anticonvulsant drug. VPA is also under clinical evaluation to be employed in anticancer therapy, as an antithrombotic agent or a…
Commentaires récents